Capricor Therapeutics, Inc. (DE:4LN2)
NASDAQ:4LN2
4LN2 Analyst Ratings
Strong Buy
8 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
4LN2 Stock 12 Month Forecast
Average Price Target
€46.65
▲(82.52% Upside)
| Highest Price Target€54.58 | Average Price Target€46.65 | Lowest Price Target€33.45 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
€52.81
Buy
106.63%
Upside
Reiterated
06/26/26
Oppenheimer
€47.53
Buy
85.97%
Upside
Reiterated
06/18/26
Roth MKM
€33.45
Buy
30.87%
Upside
Reiterated
05/29/26
Alliance Global Partners
€44.89
Buy
75.64%
Upside
Reiterated
05/14/26
JonesTrading
€44.89
Buy
75.64%
Upside
Reiterated
05/13/26
We discuss the nuances below, but the bottom line is that the US commercial agreement is not workable in its current form, and CAPR is seeking rescission after negotiations stalled. Despite initial negative stock reaction, we see this as a value-creation opportunity in the long run. Deramiocel is a multi- billion dollar opportunity in the US, and CAPR can likely launch the drug without a commercial partner. The best case scenario is that CAPR walks away from the deal, minus ~$50M in R&D payments previously received from NS Pharma.
Piper Sandler
€51.05
Buy
99.74%
Upside
Reiterated
05/13/26
Cantor Fitzgerald
€54.58
Buy
113.52%
Upside
Reiterated
05/12/26
Maxim Group
€44.01
Buy
72.19%
Upside
Reiterated
05/11/26
B. Riley Securities
€44.01→€55.46
Buy
116.96%
Upside
Assigned
03/13/26
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
€52.81
Buy
106.63%
Upside
Reiterated
06/26/26
Oppenheimer
€47.53
Buy
85.97%
Upside
Reiterated
06/18/26
Roth MKM
€33.45
Buy
30.87%
Upside
Reiterated
05/29/26
Alliance Global Partners
€44.89
Buy
75.64%
Upside
Reiterated
05/14/26
JonesTrading
€44.89
Buy
75.64%
Upside
Reiterated
05/13/26
We discuss the nuances below, but the bottom line is that the US commercial agreement is not workable in its current form, and CAPR is seeking rescission after negotiations stalled. Despite initial negative stock reaction, we see this as a value-creation opportunity in the long run. Deramiocel is a multi- billion dollar opportunity in the US, and CAPR can likely launch the drug without a commercial partner. The best case scenario is that CAPR walks away from the deal, minus ~$50M in R&D payments previously received from NS Pharma.
Piper Sandler
€51.05
Buy
99.74%
Upside
Reiterated
05/13/26
Cantor Fitzgerald
€54.58
Buy
113.52%
Upside
Reiterated
05/12/26
Maxim Group
€44.01
Buy
72.19%
Upside
Reiterated
05/11/26
B. Riley Securities
€44.01→€55.46
Buy
116.96%
Upside
Assigned
03/13/26
Best Analysts Covering Capricor Therapeutics
3 Months
Success Rate
5/12 ratings generated profit
Average Return
+35.54%
Copying Kristen Kluska's trades and holding each position for 3 Months would result in 41.67% of your transactions generating a profit, with an average return of +35.54% per trade.
1 Year
Success Rate
14/18 ratings generated profit
Average Return
+85.93%
Copying Leland Gershell's trades and holding each position for 1 Year would result in 77.78% of your transactions generating a profit, with an average return of +85.93% per trade.
2 Years
Success Rate
16/18 ratings generated profit
Average Return
+215.65%
Copying Leland Gershell's trades and holding each position for 2 Years would result in 88.89% of your transactions generating a profit, with an average return of +215.65% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
4LN2 Analyst Recommendation Trends
Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
12
10
7
17
12
Buy
2
4
5
8
4
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
14
14
12
25
16
Each month's total comprises the sum of three months' worth of ratings.
4LN2 Financial Forecast
4LN2 Stock Forecast FAQ
What is DE:4LN2’s average 12-month price target, according to analysts?
Based on analyst ratings, Capricor Therapeutics, Inc.’s 12-month average price target is 46.65.
What is DE:4LN2’s upside potential, based on the analysts’ average price target?
Capricor Therapeutics, Inc. has 82.52% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Capricor Therapeutics, Inc. a Buy, Sell or Hold?
Capricor Therapeutics, Inc. has a consensus rating of Strong Buy, which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.
What is Capricor Therapeutics, Inc.’s share price target?
The average share price target for Capricor Therapeutics, Inc. is 46.65. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €54.58 ,and the lowest forecast is €33.45. The average share price target represents 82.52% Increase from the current price of €25.56.
The highest analyst share price target is €54.58 ,and the lowest forecast is €33.45. The average share price target represents 82.52% Increase from the current price of €25.56.
What do analysts say about Capricor Therapeutics, Inc.?
Capricor Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
How can I buy shares of Capricor Therapeutics, Inc.?
To buy shares of DE:4LN2, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.